Hi ,
|
Colossal Biosciences, the George Church co-founded de-extinction company behind the efforts to bring back the woolly mammoth and the extinct carnivorous marsupial thylacine, announced today the launch of Form Bio with $30M in fresh funding. The goal of Form is less audacious, but more practical: to revolutionize the Bio-CAD software market.
|
 |
"Computer-aided design, fabrication, testing analyses and machine learning are key to the future of bioengineering in general and specifically restoration of endangered and extinct genetic diversity for keystone species in vital ecosystems. Form Bio is the software critical to pave the way. As scientist-engineers we need these pipelines and look forward to faster breakthroughs in scientific discoveries and applications, now that software has caught up with science," said Church, Professor at Harvard Medical School and MIT and director of Synthetic Biology at the Wyss Institute in Boston.
Cultivated Bison, elk, and wagyu beef, are soon to be all the
rage if Orbillion Bio continues on its groundbreaking path: announcing this week a new partnership with Dutch specialty meat distributor Luiten Food to go to market in 35 European countries. The startup is claiming it will be able to achieve price parity by as early as 2026.
|
 |
COO & Co-Founder Samet Yildirim, CEO & Co-Founder Patricia Bubner, CTO & Co-Founder Gabriel Levesque-Tremblay © Orbillion
Over the last six years, Leaps by Bayer invested roughly $1.5 billion into small biotech startups. Now, the firm plans to invest a nearly identical pot of money — this time, $1.3 billion — in half the time.
|
 |
Juergen Eckhardt is head of Leaps by Bayer, the drug giant's venture arm.
Congrats to Givaudan and LanzaTech who just announced a new collaboration on developing sustainable fragrance ingredients from renewable carbon.
And congrats to David Liu on his new patent on prime editing of DNA.
Want to meet with Leaps by Bayer, Colossal and Orbillion and over 2000 other entrepreneurs and investors face to face? Well, you can at SynBioBeta 2023, May 23-25th at the Oakland Marriott. We’re beefing up our partnership area where you’ll find networking lounges and 1:1 partnering rooms available to book. This week, new 2023 attendees just confirmed include: Synonym Biotechnologies, Arralyze, Arcaea, Raytheon BBN, and investors from First Bight Ventures and Morgan Stanley. In addition: Conagen and Inscripta just signed up to sponsor the event (Thank you!). You can learn more at: www.synbiobeta.com.
|
Have a great week.
Regards,
John
---
John Cumbers
Founder, SynBioBeta
|
|
|
|
|
 |
AlphaFold developers win $3-million breakthrough prize in life sciences |
DeepMind’s system for predicting the 3D structure of proteins is among five recipients of science’s most lucrative awards. (Scientific American)
|
Keep Reading »
|
|
 |
Mosquitoes that can’t spread malaria engineered by scientists |
If proven safe and effective in real-world settings it could offer a powerful new tool to help eliminate malaria. (Imperial College London)
|
Keep Reading »
|
|
|
 |
Download the application note to learn how Inscripta’s Onyx® Digital Genome Engineering Platform can be used for rapid strain engineering to improve heterologous protein production.
|
Keep Reading
»
|
|
 |
Microbiologists propose new DNA-based naming system for microbes |
Culturing bacteria has long been a requirement for naming a microbe, but a new system needs only its DNA sequence. (Science News)
|
Keep Reading »
|
|
|
|
|
Who's hiring?
|
- Senior Knowledge Analyst, Deep Tech, BCG, Remote, US or Europe based
- Head Of Strategy, Verb Biotics, Boston, MA
- Marketing Director, Verb Biotics, Boston, MA
- Senior Software Engineer/ Staff Software Engineer, Inscripta, Pleasanton, CA or Boulder, CO
- Senior Scientist/ Engineer, Inscripta, Pleasanton, CA
|
|
|
